![](/img/cover-not-exists.png)
2325 A study of the representativity of the NCIC, PRODIGE and MPACT phase III trials of gemcitabine-erlotinib, FOLFIRINOX and gemcitabine-nab-paclitaxel in patients with advanced pancreatic cancer treated in a real-life setting
Aknoundova, D., Diaz Beveridge, R., Escoin, C., Segura, A., Bruixola, G., Reche, E., Gimenez, A., Salvador, C., Niño, O.M., Aparicio, J.Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31241-2
Date:
September, 2015
File:
PDF, 62 KB
english, 2015